What is SS-31 and what is it used for?

SS-31 (also known as elamipretide) is a synthetic peptide designed to target the mitochondria—the tiny structures inside nearly every cell that produce the energy needed for normal cellular function.

Unlike many compounds that work by stimulating hormones or activating cell-surface receptors, SS-31 enters cells and accumulates within the inner mitochondrial membrane, where it binds to a unique phospholipid called cardiolipin. Cardiolipin is essential for maintaining the structure and efficiency of the electron transport chain, the system responsible for generating ATP, the body's primary energy molecule.

When mitochondria become damaged through aging, disease, or oxidative stress, cardiolipin can become dysfunctional, leading to reduced energy production and increased formation of reactive oxygen species (ROS). SS-31 is thought to stabilize cardiolipin, helping preserve mitochondrial structure, improve ATP production, and reduce oxidative damage without acting as a conventional antioxidant.

By improving the efficiency of mitochondrial energy production, SS-31 has been investigated in a wide range of preclinical and clinical studies involving conditions associated with mitochondrial dysfunction. Research suggests it may improve the ability of cells to produce energy while reducing cellular stress and inflammation, particularly in tissues with high energy demands such as the heart, brain, kidneys, skeletal muscles, and eyes. Rather than forcing cells to produce more energy, SS-31 appears to help mitochondria operate more efficiently, allowing damaged or aging cells to function closer to normal.

This unique mechanism has made it one of the most extensively studied mitochondria-targeted peptides currently in development.

Interest in SS-31 has grown considerably within longevity and performance research because mitochondrial dysfunction is considered a common feature of aging and many chronic diseases. Researchers have studied the peptide in models of heart failure, kidney injury, neurodegenerative disorders, ischemia-reperfusion injury, primary mitochondrial diseases, and age-related declines in muscle function and exercise capacity.

Some human clinical trials have reported improvements in measures such as mitochondrial function, walking distance, fatigue, or organ function in certain patient populations.

Outside of formal clinical research, SS-31 has attracted attention among researchers interested in healthy aging, physical performance, recovery, and fatigue resistance. The rationale is that healthier mitochondria may support better cellular energy production, faster recovery from metabolic stress, and improved resilience of tissues that rely heavily on continuous ATP generation.